Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Presentation is slick and to the point, great faith in CF to deliver the goods, and if we get a hint of good news on the Imutex/PrepBiopharm JV's then all bets are off on to how high this goes IMHO....there so much in the OO locker with all the pipelines and world leading facilities etc etc etc . we have a CEO who not only talks the talk but walks the walk and is the largest shareholder to! The orphan drug database is going to be available by year end for pharma companies to subscribe to... all of the jigsaw pieces are coming together at a fairly quick pace now .....a little more patience and I'm sure we will be rewarded for sticking with CF...if you want to trade or sell then don't cry if you get caught out by an RNS or two.. ADYOR!!!!!!!.
Hi Whitegate, it is suggested on slide 22 of the current investor presentation: https://www.openorphan.com/investors/reports-and-presentations/year/2020
Can you publish the Web site where you saw this, regarding swapping the flue vaccine for the COVID 19?
Thanks
Have you got the Web page for this so that others on this site can verify the test? Anything like this I'm sure will help!
Sorry the last paragraph was not relevant here but crucial thing from one of previous RNSs is.
The MosaiQ COVID-19 Antibody Microarray was CE marked (certified to meet EU requirements) as of 01 May 2020 based on testing that demonstrated 100% sensitivity (ability to detect COVID-19 antibodies) and 99.8% specificity (ability to rule out the presence of COVID-19 antibodies).
Those figures are fantastically high re sensitivity and specificity so very low number of false negatives and false positives so a really accurate test.
No worries Dave.Not a science guy but worked in pharma a lot of years and have experience at selling/ marketing Viral based Vax and also Rapid point of care viral testing kits along with plenty of other therapeutic areas.
Really good prospects here but just makes me laugh sometimes when people look at “ competitor” tests and worry they are going to take the market.
Firstly the market is huge on all testing whether Antibody or Antigen,whether lab based or not,whether rapid point of care or not.
Secondly they all have their benefits and USPs and will all find their levels. The huge partnership deals here are so important for external validation and how successful these tests will be dependent on specificity and sensitivity accuracy.
From what I have seen so far about the Affimer technology they are very accurate and flexible and the validation is critical
Hi Ivyspivey,
Thanks for the detailed response.
You sound like a scientist with such knowledge. I'm afraid my A Level Chemistry from many moons ago doesn't stretch that far!
Agreed on the point of Challenger studies. CF was very confident in landing these. Just hop they can pull it in from the October date he mentioned at a previous presentation. They'll be working flat out I'm sure.
ATB
Dave
Hi Dave,
Certainly not doubting the potential possibility of a universal Coronavirus Vaccine in the future but all the current 100+ candidates such as the Oxford ChAd Vax will not do this.
It was more to explain the difference between current Flu Vax which are based on predicting which antigenic field strains are likely to be in circulation and the universal one which stimulates a cell mediated and humoral response to cater for any flu strain.
The issue with Covid 19 is the need to specifically target the S and if possible the N protein and not worry too much at this stage about any potential new strains.
One further point which is interesting and made by Pascal Soriott that many of the current Covid 19 Vax May struggle to compete their trials simply due to lack of community infection.
This works in ORPHs favour in being able to doing challenge studies in U.K.- the difficulty of course is in scaling up the numbers.
ATB
Ivyspivey,
CF has spoken in at least one of his presentations that it will be possible (though not yet developed) to swap the universal flu T Cell vaccine with a universal Coronavirus one thereby encompassing covid19 and presumably mututations. Not sure which presentation it was but he has definitely said it.
Jimzi, In fairness ORPH do communicate a lot there should not need to be a need for particular BB expertise.
However,some should be made aware that there are differences between flu virus,s and Covid 19.
The idea of a universal flu Vax is one that will create an immune response to new antigenic strains that we may not predict with accuracy.
The Covid 19 Vax will not be a universal one so no MERS/SARS and will be specific vs the Spike protein and possibly N protein and may or may not work if the virus mutates.
Jim I, I don’t think we need more bb experts on here ,we are invested in ORPH and in ORPH we should trust what they say, they have the team of experts and advisors, yes we all can have an opinion but who would you listen to you / me or the team of ORPH.
Nothing less than I would expect from the Mail....but seriously, almost every Government on earth got caught-short by Covid-19....and I suspect there will be a concerted effort to be prepared for further epidemics.
So that while Covid-19 will sink slowly (12 - 18 months?) into the sunset it's legacy will include increased vaccine research (ORPH) / increased antiviral research (ORPH / SNG / ETX et al) Improved diagnostics / monitoring (ORPH / ODX et al) not to mention all the PPE consummables, and many others
Having read that article we find Flu vaccine is usually grown by vaccine manufacturers in fertilized chicken eggs. Flu- v however would be synthetically manufactured .
With strong hints that Flu-v can be modified for Covid 19, I just can’t believe it will be left on the shelf given the current global catastrophe. Would be good if we had more medical experts on the BB to assist
Probably a bit over the top but https://mol.im/a/8370969.